NYSE · RAL

Ralliant Corporation

$69.83 +$0.40 (+0.58%) 1D Pre-market

Key Metrics

$7.77B
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow
Beta · 1Y 1.64
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 12
    The stock moved +19.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 12
  • Feb 5
    From its Feb 4 high, the share price fell 32%.

    Peak close $56.28 on Feb 4; trough close $38.39 on Feb 5. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -32%
  • Feb 5
    The stock moved -31.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 5

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$7.77B
Enterprise value$8.65B
Shares outstanding111.9M
52-wk range$37.27 – $75.41
Avg volume · 20D1.7M
Net cash −$880.30M
Book value / share$13.99
IndustryIndustrial Instruments For Measurement, Display, And Control
ExchangeNYSE
About Ralliant Corporation
IPO dateJun 25, 2025
Employees7000

Ralliant Corp is a technology company with businesses that design, develop, manufacture, and service precision instruments and engineered products.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio1.61
Quick ratio1.05
Debt / equity0.73
Debt / EBITDA
Net cash −$880.30M
Working capital$350.50M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

Needs two fiscal years of filings

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-04-03 · computed by TickerWolf from SEC filings